MX2023003362A - Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. - Google Patents
Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.Info
- Publication number
- MX2023003362A MX2023003362A MX2023003362A MX2023003362A MX2023003362A MX 2023003362 A MX2023003362 A MX 2023003362A MX 2023003362 A MX2023003362 A MX 2023003362A MX 2023003362 A MX2023003362 A MX 2023003362A MX 2023003362 A MX2023003362 A MX 2023003362A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- pyrrolo
- pyridin
- treatment
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082324P | 2020-09-23 | 2020-09-23 | |
| US202063092970P | 2020-10-16 | 2020-10-16 | |
| PCT/US2021/051504 WO2022066734A1 (en) | 2020-09-23 | 2021-09-22 | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003362A true MX2023003362A (es) | 2023-05-30 |
Family
ID=78135207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003362A MX2023003362A (es) | 2020-09-23 | 2021-09-22 | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230364070A1 (enExample) |
| EP (1) | EP4217070A1 (enExample) |
| JP (1) | JP7797513B2 (enExample) |
| KR (1) | KR20230094197A (enExample) |
| AU (1) | AU2021347288A1 (enExample) |
| CA (1) | CA3196712A1 (enExample) |
| CL (1) | CL2023000856A1 (enExample) |
| IL (1) | IL301532A (enExample) |
| MX (1) | MX2023003362A (enExample) |
| TW (1) | TW202229272A (enExample) |
| WO (1) | WO2022066734A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| EP4217352A4 (en) | 2020-09-23 | 2024-04-10 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2023173083A1 (en) * | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CA3246654A1 (en) | 2022-03-24 | 2023-09-28 | Antares Therapeutics, Inc. | METHODS FOR SYNTHESIZING EGFR INHIBITORS |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| CN121712773A (zh) * | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2025049904A1 (en) | 2023-08-31 | 2025-03-06 | Scorpion Therapeutics, Inc. | Egfr inhibitor for use in the treatment of lung cancer positive for an egfr exon 20 mutation |
| EP4534085A1 (en) | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| ES2620316T3 (es) | 2012-05-11 | 2017-06-28 | Bayer Pharma Aktiengesellschaft | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| HK1218750A1 (zh) | 2013-03-21 | 2017-03-10 | Bayer Pharma Aktiengesellschaft | 3-杂芳基取代的吲唑 |
| WO2014147204A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| US9765058B2 (en) | 2013-06-21 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| HK1223097A1 (zh) | 2013-06-21 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吡唑 |
| ES2652305T3 (es) | 2013-06-21 | 2018-02-01 | Bayer Pharma Aktiengesellschaft | Pirazoles heteroaril sustituidos |
| HK1222846A1 (zh) | 2013-06-21 | 2017-07-14 | Bayer Pharma Aktiengesellschaft | 取代的苄基吡唑 |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3157914B1 (en) | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| TN2017000329A1 (en) | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| JP6141568B1 (ja) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| US20200216439A1 (en) | 2015-12-16 | 2020-07-09 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2019165385A1 (en) | 2018-02-23 | 2019-08-29 | Fulton Group N.A., Inc. | Inward-firing premix fuel combustion burner |
| EP3755323A4 (en) | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
| CN112236417A (zh) | 2018-06-14 | 2021-01-15 | 达纳-法伯癌症研究所股份有限公司 | 作为her2抑制剂的氰基喹啉酰胺化合物及使用方法 |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| DK3959211T3 (da) * | 2019-04-24 | 2026-04-27 | Bayer Ag | 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser |
| US12403135B2 (en) * | 2019-04-24 | 2025-09-02 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| US20240307362A1 (en) * | 2019-04-24 | 2024-09-19 | Bayer Aktiengesellschaft | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS |
-
2021
- 2021-09-22 KR KR1020237013431A patent/KR20230094197A/ko active Pending
- 2021-09-22 AU AU2021347288A patent/AU2021347288A1/en active Pending
- 2021-09-22 EP EP21791189.0A patent/EP4217070A1/en active Pending
- 2021-09-22 CA CA3196712A patent/CA3196712A1/en active Pending
- 2021-09-22 US US18/027,316 patent/US20230364070A1/en active Pending
- 2021-09-22 WO PCT/US2021/051504 patent/WO2022066734A1/en not_active Ceased
- 2021-09-22 JP JP2023542834A patent/JP7797513B2/ja active Active
- 2021-09-22 IL IL301532A patent/IL301532A/en unknown
- 2021-09-22 MX MX2023003362A patent/MX2023003362A/es unknown
- 2021-09-23 TW TW110135434A patent/TW202229272A/zh unknown
-
2023
- 2023-03-23 CL CL2023000856A patent/CL2023000856A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301532A (en) | 2023-05-01 |
| US20230364070A1 (en) | 2023-11-16 |
| CL2023000856A1 (es) | 2023-11-17 |
| AU2021347288A1 (en) | 2023-05-04 |
| KR20230094197A (ko) | 2023-06-27 |
| EP4217070A1 (en) | 2023-08-02 |
| AU2021347288A9 (en) | 2023-07-13 |
| CA3196712A1 (en) | 2022-03-31 |
| JP7797513B2 (ja) | 2026-01-13 |
| WO2022066734A1 (en) | 2022-03-31 |
| JP2023543528A (ja) | 2023-10-16 |
| TW202229272A (zh) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003362A (es) | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. | |
| WO2022076831A3 (en) | Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer | |
| ES2436225T3 (es) | Inhibidores TRPA1 para tratamiento del dolor | |
| KR102871791B1 (ko) | 병용 요법 | |
| CN107027291B (zh) | 用谷氨酰胺酶抑制剂的组合疗法 | |
| IL324078A (en) | Fused ring compounds | |
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| KR20250004840A (ko) | 할로겐 치환 이소인돌린 화합물 및 이의 응용 | |
| ES2176251T3 (es) | Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf). | |
| WO2022072645A3 (en) | Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer | |
| WO2016210106A1 (en) | Compositions and methods for inhibiting arginase activity | |
| EP2847186B1 (en) | Substituted aminoquinazolines useful as kinases inhibitors | |
| MX2021002109A (es) | Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer. | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| ES2401822T3 (es) | Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| MX2024003925A (es) | Terapia de combinación utilizando pirimidin-4(3h)-onas sustituidas y sotorasib | |
| MX2013015333A (es) | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos. | |
| WO2022133098A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2005058245A3 (en) | Synthetic process | |
| MX2024001817A (es) | Compuestos y composiciones para tratar condiciones asociadas con actividad de sting. | |
| WO2012054978A1 (en) | Novel anti-cancer agents | |
| KR101480481B1 (ko) | 퀴나졸린 화합물 | |
| TW200635927A (en) | Synthetic process | |
| US20080125428A1 (en) | Cancer Treatment Method |